NASDAQ : CTY
City Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 20.71 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
City Therapeutics, Inc. (CTY) reported revenue of 14.34M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 14.34M | 13.56M | 2.78M |
| Cost of Revenue | 80.36M | 58.42M | 25.68M |
| Gross Profit | -66.02M | -44.86M | -22.90M |
| Selling, General & Admin | 18.44M | 15.06M | 6.19M |
| Operating Expenses | 18.44M | 15.06M | 6.19M |
| Operating Income | -84.46M | -59.92M | -29.09M |
| Interest Expense | -3.11M | -2.26M | -448.00K |
| Interest & Investment Income | 3.74M | 4.21M | 2.40M |
| Other Non Operating Income (Expenses) | -2.81M | -534.00K | -695.00K |
| Pretax Income | -87.67M | -58.51M | -27.84M |
| Net Income | -87.67M | -58.51M | -27.84M |
| Net Income to Common | -87.67M | -58.51M | -27.84M |
| Shares Outstanding (Basic) | 5.58M | 4.70M | 3.40M |
| Shares Outstanding (Diluted) | 5.58M | 4.70M | 3.40M |
| EPS (Basic) | -15.72 | -12.46 | -8.18 |
| EPS (Diluted) | -15.72 | -12.46 | -8.18 |
| Free Cash Flow | -80.75M | -44.02M | -23.93M |
| Free Cash Flow Per Share | -14.48 | -9.37 | -7.03 |
| Operating Margin | -588.90% | -441.84% | -1,047.16% |
| Profit Margin | -611.25% | -431.39% | -1,002.02% |
| Free Cash Flow Margin | -563.00% | -324.55% | -861.34% |
| EBITDA | -83.00M | -58.75M | -28.67M |
| D&A For EBITDA | 1.46M | 1.17M | 424.00K |
| EBIT | -84.46M | -59.92M | -29.09M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 169.60M | 112.79M | 126.90M |
| Cash & Short-Term Investments | 169.60M | 112.79M | 126.90M |
| Receivables | 5.12M | 1.21M | 1.35M |
| Prepaid Expenses | 964.00K | 2.87M | 651.00K |
| Total Current Assets | 175.69M | 116.87M | 128.90M |
| Property, Plant & Equipment | 29.49M | 30.35M | 14.88M |
| Other Long-Term Assets | 2.54M | 2.55M | 1.57M |
| Total Assets | 208.61M | 149.77M | 145.35M |
| Accounts Payable | 5.11M | 2.69M | 2.34M |
| Accrued Expenses | 8.80M | 7.28M | 1.48M |
| Current Portion of Long-Term Debt | 33.09M | 10.80M | 10.28M |
| Current Portion of Leases | 5.13M | 5.08M | 3.09M |
| Current Unearned Revenue | 10.79M | 11.26M | 3.36M |
| Other Current Liabilities | 1.85M | 928.00K | 198.00K |
| Total Current Liabilities | 64.76M | 38.04M | 20.74M |
| Long-Term Debt | 31.06M | ||
| Long-Term Leases | 18.82M | 20.34M | 8.93M |
| Long-Term Unearned Revenue | 595.00K | ||
| Other Long-Term Liabilities | 693.00K | 463.00K | |
| Total Liabilities | 84.27M | 89.91M | 30.26M |
| Additional Paid-In Capital | 10.83M | 4.45M | 1.17M |
| Retained Earnings | -142.55M | -89.10M | -30.60M |
| Total Common Equity | -131.72M | -84.66M | -29.43M |
| Shareholders' Equity | 124.34M | 59.86M | 115.09M |
| Total Liabilities & Equity | 208.61M | 149.77M | 145.35M |
| Total Debt | 57.04M | 67.28M | 22.30M |
| Net Cash (Debt) | 112.57M | 45.51M | 104.60M |
| Net Cash Per Share | 20.19 | 9.69 | 30.73 |
| Filing Date Shares Outstanding | 5.29M | 5.18M | 3.40M |
| Total Common Shares Outstanding | 5.29M | 5.18M | 3.40M |
| Working Capital | 110.93M | 78.83M | 108.16M |
| Book Value Per Share | -24.91 | -16.34 | -8.64 |
| Tangible Book Value | -131.72M | -84.66M | -29.43M |
| Tangible Book Value Per Share | -24.91 | -16.34 | -8.64 |
| Machinery | 7.50M | 6.02M | 3.72M |
| Leasehold Improvements | 1.07M | 1.07M | 1.07M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -87.67M | -58.51M | -27.84M |
| Depreciation & Amortization | 1.46M | 1.17M | 424.00K |
| Other Amortization | 38.00K | 21.00K | -27.00K |
| Loss (Gain) From Sale of Assets | -26.00K | -26.00K | -131.00K |
| Stock-Based Compensation | 6.42M | 3.00M | 1.00M |
| Other Operating Activities | 7.25M | 3.15M | 1.56M |
| Change in Accounts Receivable | -3.45M | 143.00K | -1.35M |
| Change in Accounts Payable | 4.21M | 4.59M | 2.54M |
| Change in Unearned Revenue | -5.81M | 7.30M | 3.96M |
| Change in Other Net Operating Assets | -95.00K | -2.46M | -523.00K |
| Operating Cash Flow | -77.67M | -41.61M | -20.39M |
| Capital Expenditures | -3.08M | -2.40M | -3.54M |
| Sale of Property, Plant & Equipment | 27.00K | 27.00K | 158.00K |
| Investing Cash Flow | -3.05M | -2.38M | -3.38M |
| Long-Term Debt Issued | 30.00M | 15.00M | |
| Net Debt Issued (Repaid) | 30.00M | 15.00M | |
| Issuance of Common Stock | 2.16M | 894.00K | |
| Other Financing Activities | -611.00K | -35.00K | -337.00K |
| Financing Cash Flow | 101.05M | 30.86M | 149.44M |
| Net Cash Flow | 20.33M | -13.13M | 125.67M |
| Free Cash Flow | -80.75M | -44.02M | -23.93M |
| Free Cash Flow Margin | -563.00% | -324.55% | -861.34% |
| Free Cash Flow Per Share | -14.48 | -9.37 | -7.03 |
| Levered Free Cash Flow | -24.37M | ||
| Unlevered Free Cash Flow | -22.98M | ||
| Change in Working Capital | -5.15M | 9.58M | 4.62M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.04B | ||
| Enterprise Value | 926.35M | ||
| Debt / Equity Ratio | 0.46 | 1.12 | 0.19 |
| Net Debt / Equity Ratio | -0.91 | -0.76 | -0.91 |
| Net Debt / EBITDA Ratio | 1.36 | 0.78 | 3.65 |
| Net Debt / FCF Ratio | 1.39 | 1.03 | 4.37 |
| Asset Turnover | 0.09 | ||
| Quick Ratio | 2.70 | 3.00 | 6.18 |
| Current Ratio | 2.71 | 3.07 | 6.21 |
| Return on Equity (ROE) | -66.88% | ||
| Return on Assets (ROA) | -25.38% | ||
| Return on Capital Employed (ROCE) | -58.70% | -53.60% | -23.30% |
| Buyback Yield / Dilution | -37.97% |